Company Overview of DaVita Clinical Research
DaVita Clinical Research, a clinical research facility, provides kidney care research services for pharmaceutical and biotech companies. It offers early clinical research services, which include Phase I-IIb renal studies, bioequivalence studies, pharmacokinetics/pharmacodynamics, and drug delivery and administration; and clinical development services, such as clinical trial management, study design and protocol development, biostatistics, medical and scientific writing, regulatory affairs, quality assurance, and preapprovals. The company also operates a clinical network of physicians, medical groups, and dialysis centers in the United States; and develops a clinical informatics system, which...
825 South 8th Street
Minneapolis, MN 55404
Founded in 1994
Key Executives for DaVita Clinical Research
Senior Director of Business Development
Early Clinical Scientific Officer
Vice President and General Manager
Vice President of Research & Publishing and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2015.
DaVita Clinical Research Key Developments
Aethlon Medical, Inc. Announces Agreement with DaVita Clinical Research
May 20 14
Aethlon Medical Inc. announced that it has entered into a definitive agreement with DaVita Clinical Research (DCR) to provide clinical management services to support the forthcoming feasibility study of the Aethlon Hemopurifier. The clinical trial site location will be DaVita MedCenter Dialysis in Houston.
Aethlon Medical(R) Announces Agreement with DaVita Clinical Research
Feb 26 14
Aethlon Medical Inc. announced that it has reached an agreement in principle with DaVita Clinical Research to provide clinical management services that will support forthcoming studies of the Aethlon Hemopurifier(R). The Hemopurifier(R) is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients.
Raptor Pharmaceuticals and DaVita Clinical Collaborate on Nephropathic Cystinosis Program
Nov 5 13
Raptor Pharmaceuticals Corp. and DaVita Clinical Research have announced a collaboration to screen blood samples from patients with end-stage renal disease, or ESRD, in an effort to identify patients with unrecognized late-onset nephropathic cystinosis. DCR will supply blood samples with clinical data annotation from DCR's biorepository of over 4,000 patients with ESRD. The screening effort will employ high-throughput genetic sequencing of the cystinosin, lysosomal cystine transporter (CTNS) gene, mutations of which result in cystinosis. Results of the collaboration may reveal new insights into the prevalence of missed late-onset cystinosis in this at-risk patient population.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries